Lipids and Atherosclerosis Unit, GC9 Nutrigenomics, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain.
Netherlands Institute for Applied Science (TNO), Research Group Microbiology & Systems Biology, Zeist, The Netherlands.
Clin Nutr. 2019 Apr;38(2):529-538. doi: 10.1016/j.clnu.2018.03.016. Epub 2018 Apr 11.
BACKGROUND & AIMS: Insulin resistance (IR) and impaired beta-cell function are key determinants of type 2 diabetes mellitus (T2DM). Intestinal absorption of bacterial components activates the toll-like receptors inducing inflammation, and this in turn IR. We evaluated the role of endotoxemia in promoting inflammation-induced insulin resistance (IR) in the development of T2DM, and its usefulness as predictive biomarker.
We included in this study 462 patients from the CORDIOPREV study without T2DM at baseline. Of these, 107 patients developed T2DM according to the American Diabetes Association (ADA) diagnosis criteria after a median follow-up of 60 months (Incident-DIAB group), whereas 355 patients did not developed it during this period of time (Non-DIAB group).
We observed a postprandial increase in lipopolysaccharides (LPS) levels in the Incident-DIAB at baseline (P < 0.001), whereas LPS levels were not modified in the Non-DIAB. Disease-free survival curves based on the LPS postprandial fold change improved T2DM Risk Assessment as compared with the previously described FINDRISC score (hazard ratio of 2.076, 95% CI 1.149-3.750 vs. 1.384, 95% CI 0.740-2.589). Moreover, disease-free survival curves combining the LPS postprandial fold change and FINDRISC score together showed a hazard ratio of 3.835 (95% CI 1.323-11.114), linked to high values of both parameters.
Our results suggest that a high postprandial endotoxemia precedes the development of T2DM. Our results also showed the potential use of LPS plasma levels as a biomarker predictor of T2DM development. CLINICAL TRIALS.GOV.
NCT00924937.
胰岛素抵抗(IR)和β细胞功能障碍是 2 型糖尿病(T2DM)的关键决定因素。细菌成分的肠道吸收会激活诱导炎症的 toll 样受体,而这反过来又会导致 IR。我们评估了内毒素血症在促进炎症诱导的胰岛素抵抗(IR)发展为 T2DM 中的作用,及其作为预测生物标志物的有用性。
我们纳入了基线时无 T2DM 的 CORDIOPREV 研究中的 462 名患者。在中位随访 60 个月后,根据美国糖尿病协会(ADA)诊断标准,其中 107 名患者发展为 T2DM(Incident-DIAB 组),而在这段时间内,355 名患者未发展为 T2DM(Non-DIAB 组)。
我们观察到 Incident-DIAB 组在基线时餐后 LPS 水平升高(P<0.001),而 Non-DIAB 组的 LPS 水平没有改变。基于 LPS 餐后倍数变化的无病生存曲线比先前描述的 FINDRISC 评分(风险比 2.076,95%CI 1.149-3.750 与 1.384,95%CI 0.740-2.589)提高了 T2DM 风险评估。此外,将 LPS 餐后倍数变化和 FINDRISC 评分结合在一起的无病生存曲线显示,风险比为 3.835(95%CI 1.323-11.114),与两个参数的高值相关。
我们的研究结果表明,餐后高内毒素血症先于 T2DM 的发生。我们的研究结果还表明,LPS 血浆水平作为 T2DM 发展的预测生物标志物具有潜在用途。临床试验.gov.标识符:NCT00924937。